Telmisartan USP 80 mg
Antihypertensive Agent
Management of mild to moderate hypertension.
40 mg once a day.
Generally after four weeks of treatment.
The condition should be corrected, or telmisartan should be initiated under close medical supervision.
Treatment should be started under close medical supervision.
A lower starting dose of 20 mg is recommended.
40 mg.
It selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone secretion.
Food slightly reduces the bioavailability, with a reduction in AUC of about 6% with the 40 mg tablet and about 20% after a 160 mg dose.
Approximately 24 hours.
Back pain, diarrhoea, pharyngitis, headache, dizziness, pain, fatigue and nausea.
Hypotension, dizziness, and tachycardia.
No, it is not removed by haemodialysis.
No, it is contraindicated during pregnancy.
Caution is advised as telmisartan may pass into breast milk. Discontinue nursing or the drug, considering the importance of the drug to the mother.
The usual regimens may be followed as long as the patient's creatinine clearance is >30 mL/min.
Store below 30°C. Keep out from the reach of children.
Arbitel-40: NAFDAC Reg. No.: A4-5988 Arbitel-80: NAFDAC Reg. No.: A4-5989